OneSource Specialty Pharma LtdNSE: ONESOURCE
Open the OneSource Specialty Pharma Ltd page
Follow OneSource Specialty Pharma LtdFree account. Get a note when OneSource Specialty Pharma Ltd files.
Q1 FY27 earnings call · July 26, 2026

OneSource Specialty Pharma Q1 FY27 Earnings Call: Guides $400M Revenue, 40% EBITDA Margin, RFP Funnel 4X vs. Year Ago

Cofacto ResearchPublished July 26, 20266 min read
Quick summary

OneSource Specialty Pharma Ltd held its Q1 FY27 earnings call on July 24, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Performance & Key Wins

  • Rs.4,490 million revenue in Q1 FY 2026-2027, up 37% YoY, driven by broad-based growth across segments.
  • Rs.1,233 million EBITDA in Q1 FY 2026-2027, up 29% YoY and 24% QoQ, with sequential margin improvement from product mix (higher drug-device combination contribution).
  • 9 new launches and 6 new logos added in Q1 FY 2026-2027; RFP funnel ~4X vs. a year ago, spanning innovators, biosimilars, and animal health.
  • 12 inspections completed including 2 surprise FDA audits; no adverse outcomes disclosed.
  • Two customers achieved first-to-file status in the US for teriparatide, a potential future commercial opportunity for Onesource.
  • Partnership with Formycon for biosimilars manufacturing announced; semaglutide commercial launch in Canada with >40% of India's generic pens market manufactured at their site as of June 2026.

Sterile Days, Lines & Investment Phasing

  • Line 1 achieved full revenue contribution in Q1 FY 2026-2027 at 225 sterile days per year; EBITDA is not yet optimal due to upfront Opex for new lines.
  • Line 2 expected fully functional from Q2 FY 2026-2027 onwards, adding another 225 sterile days; management targets 475 sterile days in FY 2027-2028 as additional lines are installed.
  • ~$100 million capex announced in FY 2025-2026 for DDC and other sites; ~80% committed as of Q1 FY 2026-2027, with no significant additional capex expected in FY 2026-2027 beyond the remaining ~20%.
  • Biologics capacity expansion will require additional capex, but management said it will be "significantly lower" than the DDC investment (amount and timing unspecified).
  • Softgel greenfield expansion being initiated after current capacity (800M to 2.4B units) is fully utilized; full absorption expected over the next two years (FY 2026-2027 to FY 2027-2028) via CDMO tech transfers from European clients.
  • Pre-filled syringes capacity still has significant availability for new customers, contributing to growth to FY 2027-2028 and beyond.

Segment-Level Momentum & Pipeline Visibility

  • Drug-device combination (DDC) — semaglutide commercial in Canada, ~40% Indian generic pens market share, new production line online in FY 2026-2027, third line by end of FY 2026-2027, fourth line expected in FY 2027-2028; demand from "who's who of the global generic market."
  • Biologics — new contracts: animal health (Q4 FY 2025-2026), large global biosimilar for Micon (Q1 FY 2026-2027), European biotech (FY 2025-2026); commercialization beginning FY 2028-2029 and beyond; management sees need for additional mammalian and microbial capacity given pipeline visibility.
  • Injectable (SteriScience) — focused on scarcity plays (penicillins, FDA shortage list); new capabilities: pre-filled syringes and significant lyophilization capacity; H1 FY 2026-2027 shutdown to implement these additions, expected to be a significant contributor to FY 2027-2028 numbers.
  • Softgel CDMO — tech transfers from European clients underway, expected to fully absorb 2.4B-unit capacity over the next 12-15 months (through ~Q3 FY 2027-2028); current Rs.550 Cr revenue below earlier aspiration of Rs.800-900 Cr.
  • Oncology soft gel NDA launch in Q1 FY 2026-2027 for a top-10 US generic customer; only one other supplier exists, but market is small and near-term revenue contribution expected to be insignificant.
  • Order book visibility supports FY 2027-2028 revenue guidance of $400 million, with multiple pillars: DDC, biologics, softgel, and injectable (new capacity available full year FY 2027-2028).

EBITDA Trajectory, Batch Sizes & Mix

  • Q1 FY 2026-2027 EBITDA margin improved sequentially, driven by higher contribution from the drug-device combination business; management expects continued quarter-on-quarter improvement in H2 FY 2026-2027 as new lines ramp.
  • Batch size expansion from 200 liters to 500 liters underway across most geographies, which would significantly increase output from the same sterile days without additional capacity.
  • Business mix shifting toward significantly more Commercial Supply Agreements (CSAs) vs. MSA-stage work, as new capacity enables onboarding of previously constrained customers.
  • Opex leverage expected to improve once all lines are operational (targeting 475 sterile days in FY 2027-2028), with upfront costs for new lines currently weighing on EBITDA.
  • Injectable margin improvement program focused on valuing long-term supply relationships over low prices, with new capabilities (pre-filled syringes, lyophilization) expected to enhance margins.

Guidance, Milestones & Long-Term Growth

  • FY 2027-2028 guidance reiterated — organic revenue of $400 million and EBITDA margins of 40%, with strong visibility on order book and capacity utilization.
  • Beyond FY 2027-2028 — biologics segment expected to convert from development MSAs to commercial revenues starting FY 2028-2029; softgel and injectable businesses to contribute as capacities fill.
  • EU and US market openings from FY 2028-2029 and FY 2029-2030 onwards, with first-to-file customers; up to FY 2027-2028, guidance relies on emerging markets (excluding Canada).
  • Key near-term milestones — capacity addition starting Q2 FY 2026-2027, another expansion towards end of FY 2026-2027; revenue ramp-up from new lines expected in H2 FY 2026-2027.
  • Industry tailwinds — management cited over 50% of drug discovery is biologics; US and EU biosimilar guideline changes are driving demand for agile CDMO partners; biologics and drug-device combination are the fastest-growing CDMO segments globally.
  • Softgel business has not yet reached the Rs.800-900 Cr revenue aspiration; the new CDMO strategy and tech transfers are expected to close this gap over 12-15 months.

Tariffs, Supply Disruptions & Customer Diversification

  • US administration's tariff announcement on generics "after two years" — management noted it is "too early to assess" but based on the pattern of changes and backdowns seen from this administration, no long-term harm to the company or its customers is foreseen.
  • Middle East geopolitical tensions (Suez and Strait of Hormuz closures) have caused freight challenges and container constraints, but the impact on Onesource as a CDMO is muted due to ex-works contracts where additional time and cost is borne by customers.
  • Dr. Reddy's temporary API manufacturing shutdown caused a temporary disruption in supplies, but management mitigated this through a diversified customer base and ability to pull demand from other customers; capacity remained fully utilized.
  • Weight loss generics demand significantly outpaces supply — India's monthly pen volumes rose from less than 2,000 pens to 1,50,000-1,60,000 pens within one year (period to Q1 FY 2026-2027); Canada is still early but showing a clear trajectory.
  • Capacity fungibility across all lines allows shifting customers between lines as new capacity comes online; existing customers from Line 1 will be serviced from new lines as Line 2 starts.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.